RedHill Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2010
Revenue	6.53	61.8	85.76	64.36	6.29	8.36	4.01	0.1	0	7.01	Upgrade
Revenue Growth (YoY)	-89.43%	-27.94%	33.25%	923.03%	-24.75%	108.63%	3867.33%	3266.67%	-99.96%	58350.00%	Upgrade
Cost of Revenue	3.46	33.34	49.41	0	2.26	2.84	2.13	0	0	1.05	Upgrade
Gross Profit	3.07	28.46	36.35	64.36	4.03	5.52	1.88	0.1	0	5.96	Upgrade
Selling, General & Admin	30.98	64.03	87.99	25.38	29.81	19.99	20.04	5.4	4.13	4.01	Upgrade
Research & Development	3.53	7.28	29.5	0	17.42	24.86	32.97	25.24	17.77	12.7	Upgrade
Other Operating Expenses	-44.06	0	0	0	0	0	0.85	0	0.1	0	Upgrade
Operating Expenses	-9.56	71.31	117.49	25.38	47.23	44.85	53.85	30.64	22.01	16.71	Upgrade
Operating Income	12.63	-42.84	-81.14	38.98	-43.2	-39.33	-51.97	-30.54	-22	-10.75	Upgrade
Interest Expense / Income	-11.28	28.83	16.61	12.49	-0.9	-0.51	-6.43	-1.17	-0.91	0.06	Upgrade
Other Expense / Income	-	-	-	102.67	-	-	-	-	-	-0.1	Upgrade
Pretax Income	23.92	-71.67	-97.74	-76.17	-42.3	-38.82	-45.54	-29.37	-21.09	-10.71	Upgrade
Net Income	23.92	-71.67	-97.74	-76.17	-42.3	-38.82	-45.54	-29.37	-21.09	-10.71	Upgrade
Shares Outstanding (Basic)	1,278	638	468	353	284	213	171	127	88	87	Upgrade
Shares Outstanding (Diluted)	-	-	-	-	-	-	-	-	-	87	Upgrade
Shares Change	100.19%	36.43%	32.67%	24.33%	33.36%	24.71%	34.20%	44.64%	0.76%	39.83%	Upgrade
EPS (Basic)	4.00	-48.00	-84.00	-84.00	-56.00	-68.00	-104.00	-92.00	-76.00	-48.00	Upgrade
EPS (Diluted)	4.00	-48.00	-84.00	-84.00	-56.00	-68.00	-104.00	-96.00	-76.00	-52.00	Upgrade
Free Cash Flow	-35.83	-29.38	-65.16	-48.99	-40.92	-34.49	-44.92	-28.34	-17.84	-12.3	Upgrade
Free Cash Flow Per Share	-11.21	-18.41	-55.70	-55.55	-57.69	-64.84	-105.32	-89.19	-81.20	-56.80	Upgrade
Gross Margin	47.03%	46.06%	42.39%	100.00%	64.09%	66.06%	46.94%	100.00%	100.00%	85.03%	Upgrade
Operating Margin	193.45%	-69.33%	-94.61%	60.57%	-686.71%	-470.47%	-1297.03%	-30240.59%	-733400.00%	-153.22%	Upgrade
Profit Margin	366.25%	-115.97%	-113.98%	-118.36%	-672.45%	-464.35%	-1136.61%	-29079.21%	-703000.00%	-152.71%	Upgrade
Free Cash Flow Margin	-548.71%	-47.55%	-75.98%	-76.11%	-650.41%	-412.50%	-1120.91%	-28062.38%	-594666.67%	-175.35%	Upgrade
EBITDA	14.62	-34.69	-62.99	-54.94	-41.99	-39.24	-51.89	-30.5	-21.97	-10.62	Upgrade
EBITDA Margin	223.92%	-56.13%	-73.45%	-85.36%	-667.43%	-469.39%	-1295.01%	-30197.03%	-732200.00%	-151.41%	Upgrade
Depreciation & Amortization	1.99	8.15	18.15	8.75	1.21	0.09	0.08	0.04	0.04	0.03	Upgrade
EBIT	12.63	-42.84	-81.14	-63.68	-43.2	-39.33	-51.97	-30.54	-22	-10.65	Upgrade
EBIT Margin	193.45%	-69.33%	-94.61%	-98.95%	-686.71%	-470.47%	-1297.03%	-30240.59%	-733400.00%	-151.80%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).